טוען...
Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1
IMPORTANCE: Niemann-Pick disease, type C1 (NPC1) is a progressive neurovisceral disease with no US Food and Drug Administration–approved therapy. Miglustat, a drug used off-label in the United States for the treatment of NPC1, appears to stabilize neurologic disease progression. Several prospective...
שמור ב:
| הוצא לאור ב: | JAMA Neurol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Medical Association
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7489403/ https://ncbi.nlm.nih.gov/pubmed/32897301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.3241 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|